1. Home
  2. BCDA vs ROMA Comparison

BCDA vs ROMA Comparison

Compare BCDA & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • ROMA
  • Stock Information
  • Founded
  • BCDA N/A
  • ROMA 2018
  • Country
  • BCDA United States
  • ROMA Hong Kong
  • Employees
  • BCDA N/A
  • ROMA N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • ROMA Savings Institutions
  • Sector
  • BCDA Health Care
  • ROMA Finance
  • Exchange
  • BCDA Nasdaq
  • ROMA Nasdaq
  • Market Cap
  • BCDA 9.4M
  • ROMA 8.1M
  • IPO Year
  • BCDA N/A
  • ROMA 2024
  • Fundamental
  • Price
  • BCDA $2.84
  • ROMA $0.59
  • Analyst Decision
  • BCDA Strong Buy
  • ROMA
  • Analyst Count
  • BCDA 1
  • ROMA 0
  • Target Price
  • BCDA $60.00
  • ROMA N/A
  • AVG Volume (30 Days)
  • BCDA 82.8K
  • ROMA 183.1K
  • Earning Date
  • BCDA 08-07-2024
  • ROMA 08-23-2024
  • Dividend Yield
  • BCDA N/A
  • ROMA N/A
  • EPS Growth
  • BCDA N/A
  • ROMA N/A
  • EPS
  • BCDA N/A
  • ROMA N/A
  • Revenue
  • BCDA $468,000.00
  • ROMA $1,746,147.00
  • Revenue This Year
  • BCDA N/A
  • ROMA N/A
  • Revenue Next Year
  • BCDA $436.41
  • ROMA N/A
  • P/E Ratio
  • BCDA N/A
  • ROMA N/A
  • Revenue Growth
  • BCDA N/A
  • ROMA N/A
  • 52 Week Low
  • BCDA $2.62
  • ROMA $0.40
  • 52 Week High
  • BCDA $23.25
  • ROMA $11.80
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 36.78
  • ROMA N/A
  • Support Level
  • BCDA $2.85
  • ROMA N/A
  • Resistance Level
  • BCDA $3.66
  • ROMA N/A
  • Average True Range (ATR)
  • BCDA 0.30
  • ROMA 0.00
  • MACD
  • BCDA 0.04
  • ROMA 0.00
  • Stochastic Oscillator
  • BCDA 14.58
  • ROMA 0.00

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage and overcome various business matters arising from such factors related to ESG, sustainability and climate change. it provides tailored-made sustainability solutions to meet the client's specific needs. Its mission is to provide its clients with a one-stop destination for high-quality and holistic sustainability and climate change-related consulting services to support a more sustainable, balanced and inclusive future for our clients' organizations and the world.

Share on Social Networks: